{"classes":[{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated for a single participant.","groupId":"OG000","spread":"NA","value":"343"},{"groupId":"OG001","spread":"312","value":"749"},{"groupId":"OG002","spread":"471","value":"1070"},{"groupId":"OG003","spread":"1150","value":"2540"},{"groupId":"OG004","spread":"2680","value":"8050"},{"comment":"Two participants had values above the upper limit of quantification, meaning data for PK parameters could not be determined.","groupId":"OG005","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"749","value":"1890"},{"groupId":"OG002","spread":"1620","value":"3090"},{"groupId":"OG003","spread":"3050","value":"6850"},{"groupId":"OG004","spread":"26100","value":"12300"},{"comment":"Two participants had values above the upper limit of quantification, meaning data for PK parameters could not be determined.","groupId":"OG005","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"description":"AUClast was defined as the area under the plasma concentration-time curve from time 0 to the last quantifiable measurable plasma concentration of zilurgisertib.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 25 milligrams (mg) once daily (QD) administered as a monotherapy from Day 1 to Day 16.","id":"OG000","title":"Zilurgisertib 25 mg QD"},{"description":"Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.","id":"OG001","title":"Zilurgisertib 50 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.","id":"OG002","title":"Zilurgisertib 100 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.","id":"OG003","title":"Zilurgisertib 200 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.","id":"OG004","title":"Zilurgisertib 400 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.","id":"OG005","title":"Zilurgisertib 600 mg QD"}],"paramType":"MEAN","populationDescription":"PK Evaluable Population. Only participants with available data were analyzed. One participant who was supposed to receive 100 mg actually received 25 mg from Day 1 to Day 16.","reportingStatus":"POSTED","timeFrame":"Days 1 and 15 of Cycle 1: pre-dose; 2, 4, and 6-8 hours post-dose","title":"AUClast of Zilurgisertib","type":"SECONDARY","unitOfMeasure":"nanomolar x hour"}